Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OVV-03
- Development stage
- Preclinical
- Lead developer
- Li Ning
- Modality
- Gene Silencing → Gene Therapies, Oncolytic Viruses → Oncolytic Therapeutics, Gene Editing → Gene Therapies, Gene Addition/Replacement → Gene Therapies
- Administration
- Intratumoral
01
Overview
OVV-03 is a preclinical-stage oncolytic virus therapy developed by Joint Biosciences for the treatment of HER2-positive solid tumors. The therapeutic agent is based on a genetically engineered vesicular stomatitis virus (VSV) platform, specifically modified to target the Human Epidermal Growth Factor Receptor 2 (HER2). OVV-03 is designed to selectively infect and lyse tumor cells that overexpress HER2, a mechanism that not only directly reduces tumor burden but also releases tumor-associated antigens to stimulate a systemic antitumor immune response. In addition to its use as a monotherapy, Joint Biosciences is investigating OVV-03 in combination with HER2-targeted universal CAR-T (UCAR-T) cell therapies to potentially overcome the immunosuppressive microenvironment of solid tumors and enhance clinical outcomes.
- Other names
- VSV-Her2VSV-Her-2VSV-Her 2
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on OVV-03.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OVV-03.